Philips Secures FDA Clearance for Verida Spectral CT System
Philips received FDA 510(k) clearance for its Verida spectral CT system, an AI‑powered detector‑based scanner that reconstructs 145 images per second and delivers complete exams in under 30 seconds. The platform supports up to 270 examinations per day and uses a third‑generation Nano‑panel dual‑layer detector with deep‑learning reconstruction to cut noise and enhance image quality. By capturing both high‑energy and low‑energy data in a single scan, Verida provides conventional and spectral images without extra workflow steps. The system targets radiology, cardiology, interventional radiology and oncology, including low‑dose lung‑cancer screening.
First Patient Receives JANX014 Dose in Janux’s Trial for mCRPC
Janux Therapeutics announced the dosing of its first patient in a Phase I trial of JANX014, a prostate‑specific membrane antigen (PSMA)‑directed T‑cell engager for metastatic castration‑resistant prostate cancer (mCRPC). The multicenter, open‑label study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and early...
Phantom Neuro Secures Approval for Muscle-Machine Interface Trial
Phantom Neuro has received regulatory clearance to launch its first‑in‑human trial of the Phantom X muscle‑machine interface in Melbourne, Australia. The early feasibility study, called CYBORG, will enroll up to ten unilateral below‑elbow amputees who will receive a single outpatient implant...
Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study
German pharma giant Boehringer Ingelheim and China‑based Zai Lab announced a clinical collaboration to evaluate a dual DLL3‑targeting regimen in extensive‑stage small‑cell lung cancer and other neuroendocrine tumors. The Phase Ib/II study will combine Boehringer’s bispecific DLL3/CD3 T‑cell engager obrixtamig with...
GlycoNex Secures Japan’s PMDA Approval for GNX1021 Phase I Trial
GlycoNex has secured approval from Japan’s Pharmaceuticals and Medical Devices Agency to launch a first‑in‑human Phase I study of its lead ADC, GNX1021, in advanced gastrointestinal cancers. The multi‑centre trial will begin patient enrollment in Japan by June 2026, with parallel IND...
Vir Biotechnology Doses First Patient in Phase I VIR-5500 Trial
Vir Biotechnology has dosed the first patient in the expansion cohort of its Phase I trial of VIR‑5500, a PSMA‑targeted, dual‑masked T‑cell engager, for late‑line metastatic castration‑resistant prostate cancer (mCRPC). The cohort uses a step‑up regimen of 800/2000/3500 µg/kg every three weeks...
Zebra Technologies and Aiva Health Team up on Nurse Solutions
Zebra Technologies and Aiva Health have joined forces to embed Aiva’s AI‑powered Nurse Assistant into Zebra’s HC20, HC50 mobile computers and WS101‑H wearable badge. The voice‑first solution enables nurses to document, submit work orders and retrieve policies hands‑free, reducing interruptions...
AllRock Bio Begins Patient Dosing in Phase IIa ROCSTAR Trial
AllRock Bio has begun dosing the first patients in its Phase IIa ROCSTAR trial of ROC‑101, an oral pan‑ROCK inhibitor aimed at pulmonary hypertension. The multi‑center study will enroll up to 30 pulmonary arterial hypertension (PAH) patients and 10 interstitial lung...
First Patient Dosed in CatalYm’s Phase IIb Visugromab Trial
CatalYm announced the first patient has been dosed in its Phase IIb GDFATHER‑HCC‑01 trial, evaluating visugromab as a second‑line therapy for unresectable or metastatic hepatocellular carcinoma. The blinded, randomized study combines visugromab with the PD‑1 inhibitor nivolumab and the tyrosine‑kinase inhibitor...
Halozyme and Vertex Sign Deal for Hypercon Technology
Halozyme Therapeutics’ Hypercon unit has inked a global exclusive licence with Vertex Pharmaceuticals to apply its Hypercon microparticle platform to up to three drug targets. Vertex will pay Halozyme an upfront $15 million plus potential milestones and royalties on any resulting...
Rethinking the Microbiology Workflow with Smarter Tools for Faster Answers and Less Waste
Bruker unveiled an integrated microbiology platform that combines rapid identification, antimicrobial susceptibility testing, same‑day strain typing and next‑generation sequencing analytics. The MALDI Biotyper can analyze up to 600 isolates per hour on a 96‑spot plate, while the IR Biotyper delivers...
The Hidden Bottleneck in Digital Healthcare: Why Hospital Wireless Networks Are Under Pressure in 2026
Hospital wireless networks are hitting a critical bottleneck as AI‑driven diagnostics, IoMT devices, and mobile clinical workflows surge. Global AI spending in healthcare is expected to climb to $30.9 billion by 2029, generating data volumes that legacy Wi‑Fi cannot reliably handle....
Stereotaxis Launches Synchrony System for Cath Labs
Stereotaxis has received FDA 510(k) clearance to launch Synchrony, a digital platform for cardiac catheterization labs. The system features a 55‑inch 4K ultra‑high‑definition display that unifies control of disparate equipment and delivers full‑fidelity video with ultra‑low latency. Accompanying the hardware,...
Actinogen Treats First Patient in XanaMIA Trial for Alzheimer’s
Actinogen Medical has begun treating the first participant in the open‑label extension (OLE) of its Phase IIb/III XanaMIA trial for Alzheimer’s disease. The OLE allows eligible U.S. and Australian subjects to receive Xanamem 10 mg daily for up to 25 months, collecting...
MediBeacon Secures CE Mark Certification for TGFR Monitor and Sensor
MediBeacon announced that its transdermal glomerular filtration rate (TGFR) monitor and reusable sensor have earned CE Mark certification under the EU Medical Device Regulation. The Class IIa devices, part of the broader TGFR system that includes the Lumitrace injection and disposable...